Table 2.
Patient characteristics at baseline
| Number | ||
|---|---|---|
| Age (mean) | 75 | (47–90) |
| Neoadjuvant hormonal therapy | 145 | (35.98%) |
| T stage | ||
| T1a | 3 | (0.74%) |
| T1b | 5 | (1.24%) |
| T1c | 186 | (46.15%) |
| T2 | 102 | (25.31%) |
| T2a | 15 | (3.72%) |
| T2b | 16 | (3.97%) |
| T2c | 13 | (3.23%) |
| T3 | 29 | (7.20%) |
| T3a | 1 | (0.25%) |
| T3b | 5 | (1.24%) |
| T4 | 2 | (0.50%) |
| PSA concentration (ng/mL) | ||
| < 10 | 200 | (49.63%) |
| 10–20 | 127 | (31.51%) |
| > 20 | 68 | (16.87%) |
| Gleason score | ||
| ≤ 6 | 208 | (51.61%) |
| 7 | 127 | (31.51%) |
| ≥ 8 | 55 | (13.65%) |
| Risk group | ||
| Intermediate | 170 | (42.18%) |
| High | 119 | (29.53%) |
| Low | 106 | (26.30%) |
| Nadir | 0.53 | |